FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/02/2024
Voltar para busca
Dado oficial do USPTO
TWINPIGBIOLAB
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
05/02/2024
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
29/12/2021
Data de registro
17/10/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/10/2023
Última transação
17/10/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
03
Localização do titular
KR
Examinador
PERKINS, ELLEN J
Unidade examinadora
M10
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "TWINPIGBIOLAB" where the term "TWINPIG" appears in green and the term "BIOLAB" appears in blue.
Titulares e representantes
Titulares
TWINPIGBIOLAB INC.
Representantes
Leigh Ann Lindquist Sughrue Mion, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-cancer preparations; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; biopharmaceutical preparations for the treatment of cancer; pharmaceutical products for the treatment of cancer; diagnostic agents for medical purposes; drug delivery agents in the form of dissolvable filmscoating for tablets that facilitate the delivery of pharmaceutical preparations; pharmaceutical drugs for cancer treatment; medicines for human purposes for cancer treatment; pharmaceutical preparations for tumor treatment; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for use in oncology; pharmaceutical diagnostic preparations for medical purposes; ethical medicinal preparations for cancer treatment; pharmaceuticals for the treatment of cancer; non-prescription medicines for intestinal disorders and for the treatment of cardiovascular diseases; biological preparations for the treatment of cancer; pharmaceutical compounds for treating cancer
Classe 42
Scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; consultancy relating to scientific research in the field of pharmacogenetics; providing medical research information and scientific research information in the field of pharmaceuticals and clinical trials; consultancy relating to pharmaceutical research and development; pharmaceutical research and development; pharmaceutical research services; medical laboratory services; consultancy in laboratory analysis of biology sequence processing for medical research purposes; medical research laboratory services; medical research; analysis and evaluation of medical product developmentnamely new product testing and design; providing information on the testingquality evaluation and research of medical products; consultancy in the field of testingquality evaluationresearch of medical products; scientific research in the fields of medicinecancerous diseases and pharmacology; research and development of technology for biotechnology; scientific research in the fields of biomedicine; scientific research of biologics
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
18/01/2024
FIMP
FINAL DISPOSITION PROCESSED
18/01/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
17/01/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
17/10/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
17/10/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/09/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
16/08/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
16/08/2023
GPNX
NOTIFICATION PROCESSED BY IB
14/08/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/08/2023
PUBO
PUBLISHED FOR OPPOSITION
01/08/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
26/07/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
26/07/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/07/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
23/06/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/06/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/06/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/06/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/06/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
12/06/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/06/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/06/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/06/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/06/2023
RFNT
REFUSAL PROCESSED BY IB
09/01/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
17/12/2022
RFRR
REFUSAL PROCESSED BY MPU
17/12/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/10/2022
CNRT
NON-FINAL ACTION WRITTEN
06/10/2022
DOCK
ASSIGNED TO EXAMINER
28/09/2022
MAFR
APPLICATION FILING RECEIPT MAILED
15/03/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/03/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/03/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TWINPIGBIOLAB ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.